牛牛AI助理已提取核心訊息
On January 23, 2024, Johnson & Johnson reported its financial results for the fourth quarter and the full year ended December 31, 2023. The company announced a 7.3% increase in fourth-quarter sales, reaching $21.4 billion, with an operational growth of 7.2% and an adjusted operational growth of 5.7%. Excluding the COVID-19 vaccine, the operational growth was 10.9%. Fourth-quarter earnings per share (EPS) rose by 39.3% to $1.70, and adjusted EPS increased by 11.7% to $2.29. For the full year, Johnson & Johnson saw a 6.5% increase in sales to $85.2 billion, with operational growth of 7.4% and adjusted operational growth of 5.9%. The full-year EPS decreased by 15.3% to $5.20 due to a special one-time charge in the first quarter, while the adjusted EPS grew by 11.1% to $9.92. The company confirmed its 2024 guidance, projecting operational sales growth of 5.0% - 6.0% and an adjusted operational EPS of $10.55 - $10.75, indicating a mid-point growth of 7.4%. Joaquin Duato, Chairman and CEO, expressed confidence in the company's ability to lead health innovation. The report also highlighted regulatory approvals, product launches, and research advancements in various healthcare segments.
On January 23, 2024, Johnson & Johnson reported its financial results for the fourth quarter and the full year ended December 31, 2023. The company announced a 7.3% increase in fourth-quarter sales, reaching $21.4 billion, with an operational growth of 7.2% and an adjusted operational growth of 5.7%. Excluding the COVID-19 vaccine, the operational growth was 10.9%. Fourth-quarter earnings per share (EPS) rose by 39.3% to $1.70, and adjusted EPS increased by 11.7% to $2.29. For the full year, Johnson & Johnson saw a 6.5% increase in sales to $85.2 billion, with operational growth of 7.4% and adjusted operational growth of 5.9%. The full-year EPS decreased by 15.3% to $5.20 due to a special one-time charge in the first quarter, while the adjusted EPS grew by 11.1% to $9.92. The company confirmed its 2024 guidance, projecting operational sales growth of 5.0% - 6.0% and an adjusted operational EPS of $10.55 - $10.75, indicating a mid-point growth of 7.4%. Joaquin Duato, Chairman and CEO, expressed confidence in the company's ability to lead health innovation. The report also highlighted regulatory approvals, product launches, and research advancements in various healthcare segments.
2024年1月23日，強生公司公佈了截至2023年12月31日的第四季度和全年財務業績。該公司宣佈第四季度銷售額增長7.3％，達到214億美元，運營增長7.2％，調整後的運營增長5.7％。不包括 COVID-19 疫苗，業務增長爲10.9％。第四季度每股收益（EPS）增長了39.3％，至1.70美元，調整後的每股收益增長了11.7％，至2.29美元。全年強生公司的銷售額增長了6.5％，達到852億美元，運營增長了7.4％，調整後的運營增長了5.9％。由於第一季度的一次性特別收費，全年每股收益下降了15.3％，至5.20美元，而調整後的每股收益增長了11.1％，至9.92美元。該公司確認了其2024年的預期，預計營業銷售額增長5.0％至6.0％，調整後的營業每股收益爲10.55美元至10.75美元，表明中點增長7.4％。董事長兼首席執行官華金·杜阿託對公司領導健康創新的能力表示信心。該報告還重點介紹了各個醫療領域的監管批准、產品發佈和研究進展。
2024年1月23日，強生公司公佈了截至2023年12月31日的第四季度和全年財務業績。該公司宣佈第四季度銷售額增長7.3％，達到214億美元，運營增長7.2％，調整後的運營增長5.7％。不包括 COVID-19 疫苗，業務增長爲10.9％。第四季度每股收益（EPS）增長了39.3％，至1.70美元，調整後的每股收益增長了11.7％，至2.29美元。全年強生公司的銷售額增長了6.5％，達到852億美元，運營增長了7.4％，調整後的運營增長了5.9％。由於第一季度的一次性特別收費，全年每股收益下降了15.3％，至5.20美元，而調整後的每股收益增長了11.1％，至9.92美元。該公司確認了其2024年的預期，預計營業銷售額增長5.0％至6.0％，調整後的營業每股收益爲10.55美元至10.75美元，表明中點增長7.4％。董事長兼首席執行官華金·杜阿託對公司領導健康創新的能力表示信心。該報告還重點介紹了各個醫療領域的監管批准、產品發佈和研究進展。
有用
沒用